Article ; Online: Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.
Journal of clinical pharmacology
2020 Volume 60, Issue 7, Page(s) 815–825
Abstract: ... to the use of escin, an agent having potent anti-inflammatory and anti-viral effects in lung injury ... Acute lung injury (ALI) represents the most severe form of the viral infection sustained ... by coronavirus disease 2019 (COVID-19). Today, it is a pandemic infection, and even if several compounds are used ...
| Abstract | Acute lung injury (ALI) represents the most severe form of the viral infection sustained by coronavirus disease 2019 (COVID-19). Today, it is a pandemic infection, and even if several compounds are used as curative or supportive treatment, there is not a definitive treatment. In particular, antiviral treatment used for the treatment of several viral infections (eg, hepatitis C, HIV, Ebola, severe acute respiratory syndrome-coronavirus) are today used with a mild or moderate effect on the lung injury. In fact, ALI seems to be related to the inflammatory burst and release of proinflammatory mediators that induce intra-alveolar fibrin accumulation that reduces the gas exchange. Therefore, an add-on therapy with drugs able to reduce inflammation, edema, and cell activation has been proposed as well as a treatment with interferon, corticosteroids or monoclonal antibodies (eg, tocilizumab). In this article reviewing literature data related to the use of escin, an agent having potent anti-inflammatory and anti-viral effects in lung injury, we suggest that it could represent a therapeutic opportunity as add-on therapy in ALI related to COVID-19 infection. |
|---|---|
| MeSH term(s) | Acute Lung Injury/etiology ; Acute Lung Injury/physiopathology ; Anti-Inflammatory Agents/therapeutic use ; Antiviral Agents/therapeutic use ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/drug therapy ; Coronavirus Infections/physiopathology ; Drug Therapy, Combination ; Escin/administration & dosage ; Escin/pharmacology ; Escin/therapeutic use ; Humans ; Immunologic Factors/therapeutic use ; Inflammation Mediators/metabolism ; Lung/pathology ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/physiopathology ; SARS-CoV-2 |
| Chemical Substances | Anti-Inflammatory Agents ; Antiviral Agents ; Immunologic Factors ; Inflammation Mediators ; Escin (6805-41-0) |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-05-22 |
| Publishing country | England |
| Document type | Journal Article ; Review |
| ZDB-ID | 188980-1 |
| ISSN | 1552-4604 ; 0091-2700 ; 0021-9754 |
| ISSN (online) | 1552-4604 |
| ISSN | 0091-2700 ; 0021-9754 |
| DOI | 10.1002/jcph.1644 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Uf I Zs.176: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.